**Title page**

**Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: evidence from the Building Blocks trial**

**Byline**

B. Corbacho1, K. Bell1, E. Stamuli1, G. Richardson2, S. Ronaldson1, K. Hood4, J. Sanders3, M. Robling4, D. Torgerson1 on behalf of the Building Blocks trial group\*

**Department(s) and institution(s) to which the work should be attributed**

1York Trials Unit

ARRC Building, Department of Health Sciences

University of York, York

YO10 5DD, UK

2Centre for Health Economics

University of York, York

YO10 5DD, UK

3School of Healthcare Sciences,

Room 12:15, Eastgate House, 35-43 Newport Road

Cardiff. CF24 0AB

4Centre for Trials Research, Cardiff University

Neuadd Meirionnydd, Heath Park,

Cardiff, CF14 4YS

BC (Research Fellow, Health Economics) was responsible for conducting the economic evaluation and produced first draft of the paper. Dr KB (Research Fellow, Health Economics) was the second Health Economist and also conducted the economic evaluation. ES (Research Fellow, Health Economics), Dr GR (Senior Research Fellow, Health Economics) and SR (Research Fellow, Health Economics) were also Health Economists and contributed to the design and methodological approach for the health economics. JS (Senior Clinical Researcher) was responsible for the delivery of the trial. Professor KH (Professor of Medical Statistics) provided senior study design and statistical support to the trial. Professor MR (Director of Population Health Trials) was the Chief Investigator of the trial and acts as overall guarantor for the study. Professor DT (Director York Trials Unit) provided advice on the design and methodological approach for the trial as a whole and oversaw the conduct of the economic analysis.

**Details of corresponding author**

Belen Corbacho

ARRC Building, Department of Health Sciences, University of York, York, YO10 5DD, UK

Email: belen.corbacho@york.ac.uk.

Tel: +44 (0) 1904 321852 / Fax: +44 (0) 1904 321387

**Declaration of interests**

We declare no competing interests

**Key words:**

Randomised controlled trial, Cost-effectiveness, Pregnancy in adolescence, Prenatal care, Maternal health, Home visiting

**Cost-effectiveness of the Family Nurse Partnership (FNP) programme in England: evidence from the Building Blocks trial**

**Abstract**

**Rational, aims and objectives:** The Family Nurse Partnership (FNP) is a licensed intensive home visiting intervention developed in the USA. It has been provided in England by the Department of Health (DH) since 2006. The Building Blocks (BB) trial assessed the effectiveness and cost-effectiveness of FNP in England.

**Methods:** We performed a cost-utility analysis (NHS perspective) alongside the BB trial (over 2.5 years). The analysis was conducted in accordance with NICE (National Institute for Health and Clinical Excellence) reference case standards. Health-related quality of life was elicited from mothers using the EQ-5D-3L. Resource use data were collected from self-reported questionnaires, Hospital Episode Statistics (HES), general practitioner records and the central DH FNP database. Costs and quality-adjusted life years (QALYs) were discounted at 3.5%. The base case analysis used an intention to treat approach on the imputed dataset using multiple imputation (MI).

**Results:** The FNP intervention costs on average £1812 more per participant compared to usual care (95% CI -£2700; £5744). Incremental adjusted mean QALYs are marginally higher for FNP (mean difference 0.0036, 95% CI -0.017; 0.025). The probability of FNP being cost-effective is less than 20% given the current NICE willingness to pay threshold of £20 000 per additional QALY. The results were robust to sensitivity analyses.

**Conclusion:** Given the absence of significant benefits of FNP in terms of the primary outcomes of the trial and only marginal maternal QALY gains,FNP does not represent a cost-effective intervention when compared with existing services already offered to young pregnant women.

**INTRODUCTION**

The Family Nurse Partnership (FNP) programme is an intensive preventive home visiting service with positive results compared to usual services for mothers and babies both in the USA and the Netherlands [[1-4](#_ENREF_1)]. It was introduced for first time young mothers into NHS England by the Department of Health in 2006 [[5-7](#_ENREF_5)]. In October 2015 the FNP was transferred from NHS England to Local Authorities (LAs) and it is provided in approximately 125 different LAs in England. The FNP programme was introduced to be an integral part of the progressive universalism approach recommended in The Healthy Child Programme (HCP). The HCP is delivered by the Family Nurse rather than by health visitors for women who enrol onto the programme.

Given the lack of evidence on the benefits of the FNP programme in England, the Building Blocks (BB) trial was commissioned to evaluate the effectiveness and cost-effectiveness of the FNP intervention when delivered in a comprehensive publicly funded health care setting. The BB protocol has been published 11 and all amendments were reviewed and approved by the Wales NHS Research Ethics Committee (09/MRE09/08). The details of the trial design, outcomes and clinical effectiveness are reported elsewhere 12, 13. The results from the effectiveness analysis showed no statistically or clinically significant difference associated with FNP for any of the four primary outcomes: smoking cessation (adjusted OR 0·90, 97·5% CI 0·64–1·2), birth weight (adjusted mean difference 20·75 g, 97·5% CI –47·73 to 89·23), second pregnancies within two years (AOR 1·01, 0·77–1·33), or child A&E attendances and admissions to hospital (AOR 1·32, 97·5% CI 0·99–1·76, p=0.03).

This paper reports on the cost-effectiveness analysis conducted alongside the Building Blocks (BB) trial. This economic analysis also seeks to better understand a key example of an intervention that is routinely provided without clear evidence on whether it represents good value for money for the health system compared to comprehensive services, which in turn may help to guide disinvestment decisions that are unavoidable given the financial constraints within a publicly funded health care system.

**METHODS**

**Overview**

Individual patient data from the BB trial were used to perform a cost-utility analysis measuring health-related quality of life (HRQoL) in terms of quality-adjusted life years (QALYs). The analysis was from the NHS and personal social services (PSS) perspective and expressed in UK pounds sterling (2013 GBP). Costs and QALYs were discounted at a rate of 3.5% [[8](#_ENREF_8)]. We used a regression approach on an intention-to-treat (ITT) basis. The base case analysis was conducted on the dataset generated by multiple imputation by chained equations [[9](#_ENREF_9)]. Sensitivity analysis included complete case (CC) analysis to test the impact of excluding participants with missing data on the final results. All analyses and modelling were conducted in Stata 13.1 (StataCorp 2011, TX, USA).

The BB trial was a pragmatic, non-blinded, parallel-group, randomised controlled trial (RCT) which recruited within a community midwifery setting at 18 partnerships between LAs and primary and secondary care organisations in England. The trial compared two arms; usual care (through primary-care public health and social care services) plus FNP (FNP group) to usually provided health and social care alone (usual care group). These groups were followed from early pregnancy (as soon as possible from the end of the first trimester) until two years following childbirth. The trial recruited 1645 teenagers expecting their first baby, at less than 25 weeks gestation, between 16th June 2009 and 28th July 2010. The economic analysis is based on the 1618 participants that were assessed as eligible and did not withdraw consent for their data to be used. Mandatory withdrawals (e.g. miscarriage, termination for fetal anomaly) were not included in the primary analysis (FNP=26; usual care=24). Hence a total of 1568 (FNP=782; usual care=786) women were included in the base case analysis.

**Health outcomes and quality-adjusted life-years**

The primary outcome measure was QALYs, based on the EQ-5D-3LTM (EuroQoL Group Rotterdam, The Netherlands) reported by the women. The EQ-5D-3L has been used before in the UK setting within the context of a pregnant population, for example in the economic evaluation conducted alongside the Early Labour Support and Assessment (ELSA) trial [[10](#_ENREF_10)]. The EQ-5D-3L health states were valued using a UK-based social tariff [[11](#_ENREF_11)]. QALYs were calculated using the area under the curve method (AUC) [[12](#_ENREF_12)] and were adjusted for baseline utility[[13](#_ENREF_13)].

**Resource use and costs**

Costs and health outcome data were collected via self-reported questionnaires at various time-points throughout the trial: baseline, late pregnancy (34-36 weeks gestation), and 6, 12, 18 and 24 months postpartum. Baseline and 24 month data were collected by face-to-face interview by a locally based researcher. Follow-up self-reported data were collected via telephone by qualified telephone interviewers for the remainder of the time-points. Data related to the use of hospital services were obtained from maternity notes, the Health and Social Care Information Centre (HSCIC, Hospital Episode Statistics (HES)); and general practitioner (GP) visits were obtained from GP records. The cost of the FNP intervention was based on the centralised FNP Information System (IS) database run by Connecting for Health in Exeter (e.g. number of nurse visits, duration of visit, number of telephone encounters). The unit costs used to estimate the total cost per participant in the trial are presented in Table 1, sourced from the Personal Social Services Research Unit [[14](#_ENREF_14)] and NHS reference costs [[15](#_ENREF_15)].

***Table 1***

**Handling missing data**

Complete case assessment excludes all participants with any missing or incomplete data. Excluding patients with missing data leads to loss of power and biasing of the results due to a reduced sample size [[16](#_ENREF_16)]. The method we used to handle missing data was informed by the BB data. Incomplete data on costs and QALYs were imputed using multiple imputation (MI) with chained equations and predictive mean matching; which assumes that data are missing at random (MAR) [[17-19](#_ENREF_17)]. The same set of covariates as in the clinical effectiveness analysis was selected with stepwise regressions (e.g. site, smoking status, language and gestation). Rubin´s rules were used to combine point and variance estimates across imputed datasets, allowing the estimation of difference in costs and QALYs between both groups [[20](#_ENREF_20)].

**Base-case analysis**

The base-case analysis was conducted on the multiple imputed dataset, and followed an intention-to-treat (ITT) approach. For the base-case analysis total costs constituted the cost of the FNP programme (nurse time used for home based visits from the FNP nurse); GP and nurse visits (recorded in GP records), post-natal midwife and health visitor visits (self-reported by mothers); and hospital activity (HES records for inpatient admission, outpatient visits and A&E services).

The cost-effectiveness of the FNP programme was evaluated by comparing the mean differences in costs and effects in the two groups, using conventional rules and estimating the incremental cost-effectiveness ratio (ICER) as appropriate [[21](#_ENREF_21)]. The mean differences in costs and QALYs were estimated using seemingly unrelated regression (SUR) [[22](#_ENREF_22)], and their 95% confidence intervals (CI) estimated using bias corrected and accelerated (BCA) bootstrap methods. Non parametric bootstrapping [[23](#_ENREF_23)] was used to transform the uncertainty around the trial estimates into the probability that the FNP intervention is cost-effective for thresholds used by the National Institute for Health and Care Excellence (NICE) of £20 000 and £30 000 per QALY gained [[8](#_ENREF_8)], with cost-effectiveness acceptability curves (CEACs) used.

**Sensitivity analyses**

Sensitivity analyses in the base case were conducted to test the robustness of the results using five scenarios: complete case (CC) analysis according to ITT; MI removing midwife visits reported by mothers allocated to FNP (i.e. to avoid double counting in case those visits were already included in the FNP IS dataset); MI including the limited data available for mothers that withdrew due to mandatory withdrawals (i.e if FNP were to be implemented, costs related to mandatory withdrawals would be covered by the NHS); MI using self-report data (i.e including resource use exclusively related to mothers, hence excluding resource use related to babies); and MI halving the cost for the FNP intervention.

**RESULTS**

The results from the effectiveness analysis showed no statistically or clinically significant difference associated with FNP for any of the four primary outcomes: smoking cessation (adjusted OR 0·90, 97·5% CI 0·64–1·2), birth weight (adjusted mean difference 20·75 g, 97·5% CI –47·73 to 89·23), second pregnancies within two years (AOR 1·01, 0·77–1·33), or child A&E attendances and admissions to hospital (AOR 1·32, 97·5% CI 0·99–1·76, p=0.03).

**Health outcomes and quality-adjusted life-years**

Table 2 presents the proportion of participants with complete EQ-5D data. A small number of trial participants (n=10) allocated to the control arm were erroneously enrolled into FNP. Following the ITT principle they were analysed in their allocated arm regardless. Data were considered missing or incomplete when women did not complete the EQ-5D or provided a partially completed questionnaire. Two points would support the MAR assumption used as the basis for the base-case analysis: (i) the missing data followed an intermittent pattern (e.g. in both groups, more women were observed at 12 months than at six months, and the same pattern is observed at 18 and 24 months) hence complete case assessment would be, as a minimum, inefficient because it would discard observed data from individuals with some missing outcomes; and (ii) the BB data showed that participants with lower EQ-5D at baseline were more likely to have missing QALY data, which in turn suggests that the data are unlikely to be MCAR.

Participants in the FNP group started from a lower baseline HRQoL was a mean (SD) of 0.90 (0.005) (FNP) versus 0.91 (0.005) (usual care). The EQ-5D-3L scores did not differ significantly between groups at each follow-up (Table 3). The difference in mean EQ-5D-3L scores at 2 years (FNP – usual care) when controlling for baseline utility (for available cases: 320 FNP versus 265 usual care) was -0.008 (95% CI -0.023 to 0.008).

***Table 2***

Despite any difference seen in the EQ-5D-3L across the groups, this translates to very little difference in utilities (Figure I) and QALYs between the FNP and usual care groups.

***Figure 1***

**Resource use and costs**

There were no clear differences in resource use across the two groups (Table 3), though A&E attendances for mothers and babies were somewhat higher in the FNP group. Babies in the usual care group had on average longer inpatient length of stay in hospital than those babies whose mothers were randomised to the FNP intervention.

***Table 3***

Cost differences were very small across groups (Table 4). Costs associated with the delivery of the FNP intervention and the inpatient stays in hospital for babies were the major cost drivers for the cost-effectiveness. Using the principle of ITT and assigning a cost of £0.00 to women who did not receive the intervention, the average cost of nurse time for FNP visits was £3845 (SD £77), and £33 (SD £2) for FNP phone calls; however, considering only the 719 women who received the intervention, the average cost of nurse time was £4,270 (SD £1,855) per woman. If we assume that on average women were recruited at 18 weeks gestation then, the annual cost of nurse time for the FNP home visits is £1,762 per women.

**Table 4**

**Cost-effectiveness analysis**

The incremental analysis (Table 5), when adjusting for all covariates (baseline utility, site, smoking status, language and gestation), showed the FNP intervention costs on average £1811 more per participant when compared with usual care (95% CI -£2814; £5547). Incremental mean QALYs when adjusted for baseline utility are marginally higher for FNP (mean difference 0.0036, 95% CI -0.017; 0.025). This difference is even lower when adjusted for the remaining covariates (mean difference 0.0030, 95% CI -0.017; 0.027). The Net Monetary Benefit associated with the FNP intervention is negative (-£1750.57), indicating that the resources displaced would be greater than the benefit gained with the delivery of the FNP intervention. The probability of the FNP intervention being cost-effective was less than 20% given the NICE currently accepted threshold of £20 000 to £30 000 per additional QALY (Figure 2).

***Table 5***

***Figure 2***

The sensitivity analyses (Table 5) showed that the conclusions from the base case analysis were robust to all scenarios, FNP remained a non-cost-effective intervention, with the ICERs much higher than the thresholds that NICE normally consider for reimbursement decisions. Because it was felt that the cost of the intervention is the main cost driver for the analysis, the cost of the FNP intervention was halved to assess the effect on the cost-effectiveness conclusions. The mean difference in costs per participant is reduced to £360 (95% CI £-3680 to £4352); the gain in QALYs is still very marginal at 0.0047 (95% CI -0.013; 0.022). The results continue to be uncertain and the probability of FNP being cost-effective less than 50%. The complete case analysis shows that the FNP intervention cost, on average, £4549 more per woman when compared with usual care (95% CI £3175 to £5922). Participants allocated to the FNP intervention accrued fewer QALYs than those for usual Care (-0.007, 95% CI -0.042 to 0.027). Therefore the results of the complete case analysis indicate FNP was dominated by usual care.

**DISCUSSION**

This economic evaluation provides evidence that FNP is more costly than usual care and provides only a very small QALY gain. Similarly the analysis of uncertainty confirmed that it is unlikely that FNP represents an efficient intervention even if the cost was substantially reduced. The base case results indicate that the probability of FNP being cost-effective is 17%, with the results being robust to sensitivity analyses.

There is evidence of positive results of the FNP intervention in the US, a context where mothers are not able to access many statutory supportive health and social services, and maternity community based services. In contrast, pregnant women in the UK can access a wide provision of maternal care including community care family doctors, midwives and public health nurses, and as we observed in our trial sites, specialist teenage pregnancy midwives as well. It is worth it to note that the differences between the US and UK health systems can explain the lack of clinical or quality-of-life benefits for those women who receive the FNP programme as a public service offered in the UK. The Building Blocks trial is the first UK-based trial of FNP, therefore this analysis represents the most up-to-date estimate of the cost-effectiveness of FNP when delivered in a universal, publicly funded, health care setting.

There are two noteworthy limitations of this study. The first limitation relates to the level of missing data. Despite steps to minimise missing data (e.g. computer assisted telephone interviews), the number of EQ-5D questionnaires completed for each data collection wave decreased over time. This is a common problem in trial-based economic evaluations that is amplified where there are frequent assessments, as in here. It is worth noting that the use of HES data helped to minimise considerably the problem of incomplete data thus enabling more accurate estimates of hospital costs. The second limitation relates to the duration of the BB trial. In our trial we are able to assess programme cost-effectiveness in the short-term only and we recognise that for preventative programmes benefits may be expected to accrue over a longer time period and in domains of child development. Reported analyses of programme cost-effectiveness in the US have highlighted the advantage for high-risk families in particular over longer but variable periods of time. The Social Research Unit at Dartington, and Aldaba Limited conducted a cost-benefit analysis for FNP in the UK using a modelling approach which describes the longer-term savings by the FNP programme, indicating that key savings being related to higher earnings and higher attainment test scores [[24](#_ENREF_24)] There have been some shortcomings identified with the economics analyses previously reported [[25](#_ENREF_25)], for example some double counting of non-independent outcomes. In one meta-analytic review the cost savings for the programme were greatest for outcomes related to the mother (e.g. reduced crime, higher earnings, reduction in welfare) rather than the child [[26](#_ENREF_26)]. Positive programme outcomes identified the trial include maternally reported child language development. This is of potential longer-term importance but requires further evaluation over the medium term to first verify with objective ratings and second to determine whether any short-term advantage is continued to improvements in later outcomes such as school readiness. These objectives are currently being assessed in a linked study.

Besides it could be argued that we only look at QoL for the women and not the children. The EuroQol Group has developed a child-friendly EQ-5D version (EQ-5D-Y)[[27](#_ENREF_27)], however the age of 8 is the lower age limit for which the instrument is valid hence the EQ-5D-Y was not applicable for the children in the BB trial. Regarding mothers, the EQ-5D-3L did detect differences in scores between stages of pregnancy (e.g. women reported more problems in pain/discomfort and mobility at late pregnancy than any other follow-up point); which shows that this instrument can capture small yet important changes which are important to reflect the impact of the intervention on health. Similarly it could be debated that the QALY instrument lacks sensitivity for measuring the impact of FNP in health. Nonetheless within the UK the access to a new intervention has to be justified by the health gain it provides compared with usual care, where the added benefit is typically expressed in QALYs. In order to overcome the limitation of the QALY approach, this study was complemented with (i) a cost-consequence analysis (Policy Research Programme Project April 2015); and (ii) a discrete choice experiment that examined the preferences of the general population for the outcomes of the trial.

There are two main points that this study adds. From a research perspective, this study emphasises the need to conduct trials and to evaluate the effectiveness and cost-effectiveness of policy interventions before they are implemented. From a policy making perspective this study can contribute to everyday decision making regarding which services to offer to young pregnant women. Our findings provide strong evidence to suggest that the delivery of FNP is not better for young mothers or their babies than comprehensive services in the short term, while costing more. There is currently evidence supporting other cost-effective public interventions among pregnant women aiming to address some of the primary outcomes of the BB trial, with a positive influence at a relatively low cost, and maybe cost saving (e.g. smoking cessation) (Ruger et al. 2008; Tappin et al. 2015).

In England and Wales, there were 23 948 live births to women aged under 20 during 2015 (Statistics 2015)). If we assume that around 50% of these women were offered an FNP place then the annual cost saving in England from removing the FNP programme would be around £21 million.

**CONCLUSION**

The Building Blocks trial is the first UK-based trial of FNP. As discussed, the FNP intervention did not deliver significant benefits on any of the primary outcomes and only limited benefits on a small number of secondary outcomes where the risk of a chance finding is greater. Thus, taken together with the effectiveness findings, the results of this economic evaluation suggest that FNP does not represent a cost-effective intervention when adding FNP to existing services already offered to young pregnant women in England. However, it is important to note that these results are based on the two year trial only and cannot account for any longitudinal outcomes that may emerge at a later stage. Hence, at this time, we cannot recommend the continuation of FNP delivery and it may be the case that displacing the resources currently used in the FNP and investing in alternative interventions could potentially result in greater gains in child health, development and family economic stability for this population.

**ACKNOWLEDGEMENTS**

This in an independent research commissioned and funded by the Policy Research Programme in the Department of Health (reference 006/0060). The research related to human use has been complied with all the relevant national and international regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the study was approved by the Wales NHS Research Ethics Committee (09/MRE09/08) and received governance approval from all participants sited. The trial is registered with International Standard Randomised Control Trial Number ISRCTN23019866. The views expressed are not necessarily those of the Department of Health. The South East Wales Trials Unit (SEWTU) is funded by the Wales Assembly Government through the Health and Care Research Wales and the authors are gratefully acknowledge SEWTU’s contribution to study implementation. We thank all the women who participated in the study, the local professionals who facilitated the recruitment and study implementation, and the family nurses who delivered the intervention. We acknowledge all the other contributors to the study who are listed in full study report, We thank all the trial steering committee independent members: Ann Louise Kinmonth (Chair), Silvia van den Heijkant, Pamela Park, Stavros Petrou, Rachel Tonkin; and the data monitoring committee independent members: Gordon Taylor (Chair), Lucy Akhtar, Sara Kenyon. We would like to pay special tribute to the late professor Paul Wainwright who has the initial Chair of the Data Monitoring Committee. We thank the stakeholder involvement work package members: Joyce Kenkre (lead), Lily Bidmead, Kamila Hawthorne, Lesley Lowes, with contributions from members of the Books & Babies Group, and the Young Mums Groups. The trial administrators were Jackie Swain, Katy Addison, and Rhys Thomas.

**References**

1. Kitzman H, Olds DL, Henderson CR, et al. Effect of prenatal and infancy home visitation by nurses on pregnancy outcomes, childhood injuries, and repeated childbearing: a randomized controlled trial. JAMA 1997;**278**(8):644-52

2. Mejdoubi J, van den Heijkant SC, van Leerdam FJ, Crone M, Crijnen A, HiraSing RA. Effects of nurse home visitation on cigarette smoking, pregnancy outcomes and breastfeeding: A randomized controlled trial. Midwifery 2014;**30**(6):688-95

3. Olds DL, Henderson CR, Tatelbaum R, Chamberlin R. Improving the delivery of prenatal care and outcomes of pregnancy: a randomized trial of nurse home visitation. Pediatrics 1986;**77**(1):16-28

4. Olds DL, Robinson J, O’Brien R, et al. Home visiting by paraprofessionals and by nurses: a randomized, controlled trial. Pediatrics 2002;**110**(3):486-96

5. Barnes J. Nurse-family partnership programme: first year pilot site implementation in England: pregnancy and the post-partum period. 2008

6. Barnes J. Nurse-family partnership programme second year pilot sites implementation in England the infancy period. 2009

7. Barnes J, Ball M, Meadows P, et al. The Family-Nurse Partnership programme in England: Wave 1 implementation in toddlerhood and a comparison between Waves 1 and 2a of implementation in pregnancy and infancy. 2011

8. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE, 2013.

9. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics 2014;**32**(12):1157-70

10. Spiby H. Improving care at the primary/secondary interface: a trial of community-based support in early labour. The ELSA trial. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R&D (NCCSDO) 2008

11. Dolan P, Gudex C, Kind P, Williams A. A social tariff for Euroqol: Results from a UK general population survey. York: Centre for Health Economics Discussion Paper. Sep; 138, 1995.

12. Billingham L, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health technology assessment (Winchester, England) 1998;**3**(10):1-152

13. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility. Health economics 2005;**14**(5):487-96

14. Curtis L. Unit Costs of Health and Social Care 2013. University of Kent: Personal Social Services Research Unit, 2013.

15. Department of Health. NHS Reference Costs 2012/13. . https://[www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013](http://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013), 2013.

16. Little RJ, Rubin DB. The analysis of social science data with missing values. Sociological Methods & Research 1989;**18**(2-3):292-326

17. Manca A, Palmer S. Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials. Applied health economics and health policy 2005;**4**(2):65-75

18. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat. Med. 2011;**30**(4):377-99

19. Carlin JB, Galati JC, Royston P. A new framework for managing and analyzing multiply imputed data in Stata. Stata Journal 2008;**8**(1):49-67

20. Rubin DB. *Multiple imputation for nonresponse in surveys*: John Wiley & Sons, 2004.

21. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J. Health Econ. 1993;**12**(4):459-67

22. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;**14**(5):487-96 doi: 10.1002/hec.944[published Online First: Epub Date]|.

23. Efron B, Tibshirani RJ. *An introduction to the bootstrap*: CRC press, 1994.

24. Social Research Unit D. <http://investinginchildren.eu/interventions/family-nurse-partnership>.

25. Stamuli E, Richardson G, Duffy S, Robling M, Hood K. Systematic review of the economic evidence on home visitation programmes for vulnerable pregnant women. Br. Med. Bull. 2015;**115**(1):19-44

26. Aos S, Lieb R, Mayfield J, Miller M, Pennucci A. Benefits and costs of prevention and early intervention programs for youth: Olympia: Washington State Institute for Public Policy, 2004.

27. Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual. Life Res. 2010;**19**(6):875-86

***Table 1 Unit costs used for costing primary care and community services***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Item** | **Unit**  | **Cost** | **Reference** | **Notes** |
| **GP**  | Per Surgery consultationlasting 11.7 minPer out of surgery (home visiting) lasting 23.4 min | £45£114 | Unit Costs of Health and Social Care 2013 | Including direct care staff costs & qualifications |
| **GP Nurse**  | Per Surgery consultationlasting 15.5 minutesPer home visiting lasting 23.4 min | £13.4£27.3 | Unit Costs of Health and Social Care 2013 | Assume same duration than GP home visit |
| **Midwife**  | Antenatal visit(Community)Postnatal visit(Community)Home visitMidwife episode | £51£68£70£65 | NHS reference costs 2012/2013(NHS trusts and NHS foundation trusts)Unit Costs of Health and Social Care 2013 | Community Health Services – Health Visiting and MidwiferyTotal Outpatient attendances data |
| **Health visitor** | Per hourPer hour of home visiting | £49£71 | Unit Costs of Health and Social Care 2010 | Assume same duration than GP home visits |
| **Counsellor** | Surgery consultation | £58 | Unit Costs of Health and Social Care 2013 |  |
| **Mental health** | Per hour per team member | £36 | Unit Costs of Health and Social Care 2013 | Community mental health team for adults with mental health problems. |
| **Crisis Resolution team**  | Per hour per team member | £37 | Unit Costs of Health and Social Care 2013 |  |
| **Support worker** | Per hour | £22 | Unit Costs of Health and Social Care 2013 |  |
| **Social worker**  | Per hour  | £79 | Unit Costs of Health and Social Care 2013 |  |
| **Physiotherapist** | Surgery session per hourHospital session per hour | £34£36 | Unit Costs of Health and Social Care 2013 |  |
| **FNP Supervisor Nurse** | Clinic or phone visitper minute Home visit per minute | £1.34£1.62 | Unit Costs of Health and Social Care 2013 | Qualified nursing, midwifery & health visiting staff by Agenda for change band 8a, NHS England. Ratio of direct time on:Home visits (1:0.45)Patient work (1:0.20) |
| **FNP Nurse** | Clinic or phone visitper minuteHome visit per minute | £1.17£1.41 | Unit Costs of Health and Social Care 2013 | Qualified nursing, midwifery & health visiting staff by Agenda for change band 7, NHS England. Home visits (1:0.45)Patient work (1:0.20) |

***Table 2 Complete cases***

|  |  |
| --- | --- |
|  | **Complete Cases** |
|  | FNP (n=808) | Usual Care (n=810) |
| EQ-5D Baseline | 808 (100%) | 807 (99%) |
| EQ-5D 34-36 weeks | 614 (76%) | 616 (76%) |
| EQ-5D 6 months | 507 (63%) | 469 (58%) |
| EQ-5D 12 months | 510 (63%) | 480 (59%) |
| EQ-5D 18 months | 499 (62%) | 465 (57%) |
| EQ-5D 24 months | 583 (72%) | 537 (66%) |
| EQ-5D all assessments | 349 (41%) | 265 (34%) |
| GP records | 480 (61%) | 471 (60%) |
| Hospital data (HES records) | 808 (100%) | 810 (100%) |
| Complete-Case dataset ^ | 217 (28%) | 186 (24%) |

^ The complete dataset used for the base-case analysis comprised all mothers whose all six EQ-5D-3L assessments and all costs (GP records, health visitor/midwife visits and hospital attendances) were available.

***Table 3 Mothers and babies average resource use per arm of the trial from baseline up to two years following child birth***

|  |  |  |
| --- | --- | --- |
|   | **FNP (n=782)**  | **Usual Care (n=786)**  |
|   | **n** | **Mean (SD)** | **Min, Max** | **Median**  | **Missing**  | **n** | **Mean (SD)** | **Min; Max** | **Median**  | **Missing**  |
| **GP surgery visits for mothers** | 471 | 9.55 (8.40) | 0; 48 | 7 | 39.76% | 480 | 8.49 (7.81) | 0; 48 | 7 | 38.93% |
| **GP home visits for mothers** | 471 | 0.22 (0.84) | 0; 9 | 0 | 39.76% | 480 | 0.21 (0.76) | 0; 8 | 0 | 38.93% |
| **Nurse surgery visits for mothers** | 471 | 2.14 (3.61) | 0; 36 | 1 | 39.76% | 480 | 2.22(3.01) | 0; 20 | 1 | 38.93% |
| **Community Midwife visits** | 459 | 10.40 (5.34) | 0;41 | 10 | 41.30% | 422 | 10.68 (5.25) | 0; 41 | 10 | 46.31% |
| **Community Health visitor visits** | 363 | 8.60 (13.74) | 0; 68 | 0 | 53.58% | 321 | 16.25 (12.15) | 0;73 | 13 | 59.16% |
| **Community Counsellor visits** | 612 | 0.29 (1.23) | 0;12 | 0 | 21.73% | 614 | 0.32 (1.64) | 0;20 | 0 | 21.88% |
| **Inpatient Length of Stay mothers** | 782 | 3.98 (6.35) | 0; 99 | 3 | 0% | 786 | 4.09 (6.39) | 0;110 | 2 | 0% |
| **Day case admissions for mothers** | 782 | 3.53 (5.19) | 0; 60 | 2 | 0% | 786 | 3.57 (5.48) | 0;77 | 2 | 0% |
| **Outpatient visits for mothers** | 782 | 8.61 (8.05) | 0; 74 | 7 | 0% | 786 | 8.55 (8.05) | 0; 70 | 6.5 | 0% |
| **A&E attendances for mothers** | 782 | 4.54 (2.43) | 0; 36 | 1 | 0% | 786 | 1.58 (2.55) | 0; 29 | 1 | 0% |
| **GP surgery visits for babies** | 471 | 8.17 (7.10) | 0; 70 | 7 | 39.76% | 480 | 7.60 (6.20) | 0; 51 | 7 | 38.93% |
| **GP home visits for babies** | 471 | 0.29 (1.25) | 0; 17 | 0 | 39.76% | 480 | 0.29 (1.61) | 0; 20 | 0 | 38.93% |
| **Nurse surgery visits for babies** | 471 | 0.88 (2.17) | 0; 22 | 0 | 39.76% | 480 | 0.90 (2.05) | 0; 18 | 0 | 38.93% |
| **Inpatient length of stay for babies** | 724 | 2.82 (21.32) | 445 ;0 | 0 | 0% | 757 | 3.10 (25.29) | 0; 466 | 0 | 0% |
| **Day case admissions for babies** | 724 | 1.74 (3.42) | 0;34 | 0 | 0% | 757 | 1.79 (3.31) | 0; 32 | 0 | 0% |
| **Outpatient visits for babies** | 724 | 1.82 (5.29) | 0;69 | 0 | 0% | 757 | 2.08 (7.03) | 0; 135 | 0 | 0% |
| **A&E attendances for babies** | 724 | 2.58 (3.24) | 0; 30 | 2 | 0% | 757 | 2.21 (2.53) | 0; 15 | 1 | 0% |
| **FNP visits/encounters** | 709 | 39.28 (15.19) | 1; 88 | 41 | 10% | 10 | 0.45 (4.26) | 0; 53 | 0 | NA |
| **FNP phone calls**  | 709 | 6.29 (5.34) | 2; 31 | 4 | 10% | 10 | 0 | 0 | 0 | NA |

SD, standard deviation

***Table 4 Costs associated with all available cases: mean and standard deviation (in brackets). Costs discounted from year 2 at 3.5% according to ITT. Mean incremental costs and 95% CI estimated using OLS regression***

|  |  |  |
| --- | --- | --- |
|   | **Mean cost £ (SD)** | **Difference (FNP - Usual Care) (95% CI)** |
|   | **FNP** | **Usual Care**  |
| **GP surgery visits for mothers** | 429.95 (17.49) | 382.35 (16.20) | 47.60 (0.82; 94.37) |
| **GP home visits for mothers** | 25.82 (4.42) | 24.92 (4.18) | 0.89 (-11.96; 12.84) |
| **Nurse surgery visits for mothers** | 21.17 (1.69) | 22.63 (1.41) | -0.83 (-5.17; 3.50) |
| **Community Midwife visits**  | 15.51 (332.38) | 15.29 (314.19) | -20.96 (-63.82; 21.89) |
| **Community Health visitor visits** | 135.67 (11.34) | 217.78 (10.25) | -82.10 (-112.42; -51.78) |
| **Community Counsellor visits** | 16.86 (71.56) | 19.08 (94.79) | -11.62; 7.20) |
| **Inpatient length of stay mothers** | 6354.57 (8460.72) | 6661.17 (9679.04) | -306.59 (-1193.20; 580.00) |
| **Day case admissions for mothers** | 775.22 (1041.62) | 781.72 (1216.929) | -6.50 (-116.98; 103.96) |
| **Outpatient visits for mothers** | 889.49 (903.30) | 875.63 (918.99) | 13.85 (-75.01; 102.71) |
| **A&E attendances for mothers** | 167.06 (277.82) | 172.79 (289.34) | -5.72 (-33.39; 21.93) |
| **GP surgery visits for babies** | 367.74 (14.92) | 342.37 (12.80) | 25.36 (-13.13; 63.86) |
| **GP home visits for babies** | 33.13 (6.64) | 32.64 (8.38) | 0.49 (-20.57; 21.56) |
| **Nurse surgery visits for babies** | 8.96 (1.03) | 9.21 (0.95) | -0.25 (-3.00; 2.50) |
| **Inpatient length of stay for babies**  | 3773.35 (25939.83) | 4882.99 (50019.88) | -1109.634 (-5198.32979.6) |
| **Day case admissions for babies** | 142.02 (702.62) | 145.17 (615.10) | -3.15 (-70.38; 64.08) |
| **Outpatient visits for babies** | 290.96 (983.72) | 272.92 (842.08) | -18.03 (-111.56; 75.49) |
| **A&E attendances for babies** | 293.12 (370.60) | 254.93 (298.36) | 38.16 (3.94; 72.38) |
| **FNP visit/encounters** | 3845.32 (76.69) | 47.27 (16.08) | 3798.05 (3644.70; 3951.4) |
| **FNP phone calls** | 33.27 (2.84) | 0 (0) | 33.27 (27.70; 38.83) |

SD, standard deviation

***Table 5 Summary of incremental analysis (ITT), cost-effectiveness results and uncertainty for the base case (highlighted) and sensitivity analyses***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Analysis** | **Difference in costs\*** | **Difference in QALYs\***  | **ICER for FNP intervention (£ per QALY)** | **Probability FNP Cost-effective† £20 000/QALY** |
| **Base case (MI)** | **1812 (-2814; 5447)** | **0.0030 (-0.01; 0.02)** | **Above £100,000 per QALY** |  **17%** |
| Sensitivity i (CC) | 4549(3175; 5922) | -0.007(-0.042; 0.027) | FNP dominated | 0% |
| Sensitivity ii | 1933 (-2641;5654 ) | 0.005(-0.017; 0.027) | Above £100,000 per QALY | 16% |
| Sensitivity iii | 2061(-1949; 6072) | 0.005 (-0.014; 0.025) | Above £100,000 per QALY | 17% |
| Sensitivity iv | 3272 (2288; 4295) | 0.004(-0.018; 0.025) | Above £100,000 per QALY |  0% |
| Sensitivity v  | 360 (-3680; 4352) | 0.005 (-0.013; 0.022) | £73,924 per QALY | 45% |